Capstone Therapeutics (NASDAQ: CAPS)

Capstone Therapeutics (NASDAQ: CAPS), a biotechnology company, is focused on developing a pipeline of innovative therapeutic peptides designed to help patients with under-served medical conditions. The Company is currently committed to developing and commercializing two product platforms: AZX100 and Chrysalin® (rusalatide acetate or TP508). AZX100 is currently under evaluation for commercially significant medical applications such as treating pulmonary disease, and Chrysalin is currently under evaluation for treating disorders that involve vascular endothelial dysfunction. For further information, visit the Company’s web site at www.capstonethx.com.